Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial

DJ Klein, T Battelino, DJ Chatterjee… - Diabetes technology …, 2014 - liebertpub.com
Background: The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …
被引用次数：105 相关文章
[HTML] nih.gov

[HTML][HTML] Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled …

DJ Klein, T Battelino, DJ Chatterjee… - Diabetes Technology …, 2014 - ncbi.nlm.nih.gov
Background: The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …
[PDF] academia.edu

[PDF][PDF] Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled …

DJ Klein, T Battelino, DJ Chatterjee… - DIABETES …, 2014 - academia.edu
Background: The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …
[PDF] researchgate.net

[PDF][PDF] Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled …

DJ Klein, T Battelino, DJ Chatterjee… - DIABETES …, 2014 - researchgate.net
Background: The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …

Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

DJ Klein, T Battelino, DJ Chatterjee… - Diabetes Technology …, 2014 - europepmc.org
Background The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …

Liraglutide's safety, tolerability, pharmaokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

D Klein, T Battelino, D Chatterjee… - Diabetes Technol …, 2014 - researchportal.vub.be
BACKGROUND: The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …

Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial

DJ Klein, T Battelino, DJ Chatterjee, LV Jacobsen… - 2014 - pubmed.ncbi.nlm.nih.gov
Background The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …

Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

DJ Klein, T Battelino, DJ Chatterjee… - Diabetes Technology …, 2014 - europepmc.org
Background The prevalence of type 2 diabetes (T2D) in youth is increasing. Treatment
options beyond metformin and insulin are needed. The safety, tolerability, pharmacokinetics …